News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Sotorasib improves PFS over docetaxel in KRASG12C-mutated advanced NSCLC
15 Dec 2022
byRoshini Claire Anthony
The first-in-class KRASG12C inhibitor sotorasib significantly improved progression-free survival (PFS) in patients with previously treated non-small cell lung cancer (NSCLC) with KRASG12C mutations, according to results of the phase III CodeBreaK 200 trial presented at ESMO 2022.
15 Dec 2022







